Drug Trial Radar · NCT04130997
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Nov 18, 2019
Primary completion
May 31, 2032
Study completion May 31, 2032
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Conditions
- Relapsing Multiple Sclerosis (RMS)
Interventions
UblituximabBiological
Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Up to Week 336
Locations
86 sites in 8 countries. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Pasadena, California
TG Therapeutics Investigational Trial Site
Denver, Colorado
TG Therapeutics Investigational Trial Site
Miami, Florida
TG Therapeutics Investigational Trial Site
Tampa, Florida
TG Therapeutics Investigational Trial Site
Northbrook, Illinois
TG Therapeutics Investigational Trial Site
Kansas City, Kansas
TG Therapeutics Investigational Trial Site
Detroit, Michigan
TG Therapeutics Investigational Trial Site
Las Vegas, Nevada
TG Therapeutics Investigational Trial Site
Teaneck, New Jersey
TG Therapeutics Investigational Trial Site
Albuquerque, New Mexico
TG Therapeutics Investigational Trial Site
Amherst, New York
TG Therapeutics Investigational Trial Site
Columbus, Ohio
TG Therapeutics Investigational Trial Site
Westerville, Ohio
TG Therapeutics Investigational Trial Site
Knoxville, Tennessee
TG Therapeutics Investigational Trial Site
Dallas, Texas
TG Therapeutics Investigational Trial Site
Frisco, Texas
TG Therapeutics Investigational Trial Site
Round Rock, Texas
TG Therapeutics Investigational Trial Site
San Antonio, Texas
TG Therapeutics Investigational Trial Site
Seattle, Washington
TG Therapeutics Investigational Trial Site
Grodno, Belarus
TG Therapeutics Investigational Trial Site
Grodno, Belarus
TG Therapeutics Investigational Trial Site
Minsk, Belarus
TG Therapeutics Investigational Trial Site
Minsk, Belarus
TG Therapeutics Investigational Trial Site
Minsk, Belarus
TG Therapeutics Investigational Trial Site
Osijek, Croatia
TG Therapeutics Investigational Trial Site
Varaždin, Croatia
TG Investigational Trial Site
Zagreb, Croatia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
TG Therapeutics Investigational Trial Site
Katowice, Poland
TG Therapeutics Investigational Trial Site
Katowice, Poland
TG Therapeutics Investigational Trial Site
Katowice, Poland
TG Therapeutics Investigational Trial Site
Krakow, Poland
TG Therapeutics Investigational Trial Site
Lodz, Poland
TG Therapeutics Investigational Trial Site
Olsztyn, Poland
TG Therapeutics Investigational Trial Site
Poznan, Poland
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.